Likewise, immunization of stage IIIc/IV melanoma patients with autologous, peptide-pulsed CD1c+ mDC promoted Ag-specific CD8+ T cell responses in 33% of tested patients and induced long-term progression-free survival (12–35 months) in nearly 30% of patients (43). Here, CD8A is linked to melanoma.